Galmed Sets 1-for-8 Reverse Split for August 19
GLMD sits 19% above its 52-week low of $0.411.
Summary
Galmed Pharmaceuticals announced a 1-for-8 reverse share split effective August 19, 2026, reducing outstanding shares from 8.33 million to approximately 1.04 million.
Key Events · Corporate Governance and Compliance · GLMD
-
1-for-8 Reverse Split Announced
Effective August 19, 2026, every eight ordinary shares will be consolidated into one.
-
Share Count Reduction
Outstanding shares drop from 8,332,518 to approximately 1,041,565, with authorized capital set at 112,500,000 shares.
-
Nasdaq Compliance Motivation
The reverse split is likely aimed at raising the share price to meet Nasdaq's minimum bid requirement, given the stock trades at $0.49.
-
New CUSIP Number
The ordinary shares will trade under CUSIP M47238205 following the split.
Analysis · GLMD · Life Sciences
Galmed Pharmaceuticals will consolidate every eight ordinary shares into one, reducing the outstanding count from 8.33 million to about 1.04 million shares. The move is designed to lift the share price above Nasdaq's minimum bid requirement, but it also signals the company's stock has been under pressure. The reverse split takes effect August 19, 2026, and the new CUSIP is M47238205.
At the time of this filing, GLMD was trading at $0.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.41 to $1.65. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.